Biocryst Pharmaceuticals (BCRX) Current Leases (2017 - 2026)

Biocryst Pharmaceuticals' Current Leases history runs 10 years deep, the most recent figure standing at $1.2 million for Q1 2026.

• Quarterly Current Leases fell 31.2% year-over-year to $1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (down 31.2% YoY) and the FY2025 annual result came in at $317000.0, down 82.72% from the prior year.
• Current Leases was $1.2 million for Q1 2026 at Biocryst Pharmaceuticals, up from $317000.0 in the prior quarter.
• Across five years, Current Leases topped out at $2.5 million in Q2 2023 and bottomed at $317000.0 in Q4 2025.
• A 5-year average of $1.5 million and a median of $1.7 million in 2024 frame the typical range for Current Leases.
• Annual changes were most pronounced in 2022 — Current Leases jumped 117.53% — and 2025, when it slumped 82.72%.
• Biocryst Pharmaceuticals' Current Leases stood at $1.5 million in 2022, then slumped by 30.21% to $1.1 million in 2023, then soared by 73.44% to $1.8 million in 2024, then slumped by 82.72% to $317000.0 in 2025, then soared by 289.59% to $1.2 million in 2026.
• Business Quant data shows BCRX's Current Leases at $1.2 million in Q1 2026, $317000.0 in Q4 2025, and $348000.0 in Q3 2025.